Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted Antiestrogens to Prevent Breast Cancer.

Jordan1

  • 1Lynn Sage Breast Cancer Research Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 303 E. Chicago Avenue, 8258 Olson, Chicago, IL 60611, USA.

Trends in Endocrinology and Metabolism: TEM
|February 7, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immediate reconstruction of the anal sphincter after fistulectomy in the management of complex anal fistulas.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2013
Same author

Causal implications of viscous damping in compressible fluid flows

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2001
Same author

Asymptotic convergence rate of the EM algorithm for gaussian mixtures

Neural computation·2000
Same author

Disorders of Sinus Function.

Current treatment options in cardiovascular medicine·2000
Same author

Understanding the Antiestrogenic Actions of Raloxifene and a Mechanism of Drug Resistance to Tamoxifen.

Breast cancer (Tokyo, Japan)·2000
Same author

Frequent Allelic Loss at 6q26-27 in Breast Carcinomas of the Solid-tubular Histologic Type.

Breast cancer (Tokyo, Japan)·2000
Same journal

Beyond fat storage: neuronal lipid droplets regulate whole-body metabolism.

Trends in endocrinology and metabolism: TEM·2026
Same journal

HDL resuscitates cells from ferroptosis.

Trends in endocrinology and metabolism: TEM·2026
Same journal

2-Methylbutyrylcarnitine (2MBC).

Trends in endocrinology and metabolism: TEM·2026
Same journal

Decoding growth hormone actions on human growth plate stem cells.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Androgen loss backfires: Brain gate for tumor immunity.

Trends in endocrinology and metabolism: TEM·2026
Same journal

Glucocorticoid resistance-induced inflammation drives cardiovascular-kidney-metabolic (CKM) syndrome pathophysiology.

Trends in endocrinology and metabolism: TEM·2026
See all related articles

Selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene show promise in reducing breast cancer risk and improving bone density. The large STAR trial is evaluating these benefits, with results expected within seven years.

Area of Science:

  • Pharmacology
  • Oncology
  • Endocrinology

Background:

  • Selective estrogen receptor modulators (SERMs) represent a significant advancement in hormone therapy.
  • Tamoxifen, the first SERM, has demonstrated efficacy in reducing breast cancer risk and enhancing bone density.
  • Raloxifene is approved for osteoporosis prevention and shows preliminary breast cancer risk reduction.

Purpose of the Study:

  • To evaluate the comparative efficacy of tamoxifen and raloxifene in breast cancer prevention.
  • To assess the impact of these SERMs on bone density in women at risk for breast cancer.
  • To gather further clinical evidence on the long-term benefits and risks of SERMs.

Main Methods:

  • The Study of Tamoxifen and Raloxifene (STAR) is a large-scale, prospective clinical trial.

Related Experiment Videos

  • Participants are women at increased risk for breast cancer.
  • Randomized controlled trial design comparing tamoxifen and raloxifene.

    • Main Results:

    • Preliminary data suggests both tamoxifen and raloxifene may reduce breast cancer incidence.
    • Further analysis is ongoing to determine the full spectrum of benefits, including effects on bone health.
    • The STAR trial is designed to provide robust evidence over a seven-year period.

    Conclusions:

    • SERMs like tamoxifen and raloxifene hold significant potential for breast cancer prevention.
    • Ongoing research through the STAR trial will elucidate their comparative effectiveness and safety profiles.
    • These findings are crucial for informing clinical practice and public health strategies regarding breast cancer risk reduction.